Cambridge Enterprise

One week until these free scale-up workshops at Cambridge Tech Week. As proud sponsors of Cambridge Tech Week, if you’re interested in taking your business to the next level, we invite you to sign up for these FREE scale-up workshops taking place on Thursday 12 September. Whether you’re looking to expand internationally, navigate the complexities of scaling up, or leverage AI to grow your business, these workshops will equip you with actionable strategies moving forward. • Scaling Globally: International Expansion and Equity Funding with Team Compass - HSBC UK • The Scale-Up Journey: Challenges, Opportunities, and Strategies with Mills & Reeve • Maximising Your Grant Funding with MPA • Harnessing AI for Global Business Growth with the Department for Business and Trade For more info and to sign up, visit: https://vist.ly/3hkxs #CamTechWeek #ScaleUp #Workshops

Ahead of speaking at Cambridge Tech Week, Dr Christine Martin, Head of Ventures at Cambridge Enterprise, shares her insights on the role of the University of Cambridge as a pivotal investor in tech innovation. Find out more: https://lnkd.in/eVt-_Vrj Don't miss the experts from Cambridge Enterprise speaking at Cambridge Tech Week, 9-13 September: ✨ Dr Christine Martin will be speaking at Innovation Day, Tuesday 10 September AM at Cambridge Guildhall ✨ Marina Gonzalo Soares speaking on 'Commercialising University of Cambridge Innovation' at the Welcome to Cambridge event on Monday 9 September at The Bradfield Centre ✨ Gerard Grech CBE will be speaking on 'Scaling in the UK' at Scale-Up Day on Thursday 12 September at The Cambridge Union #CamTechWeek #Innovation #TechForGood #techinvestment #scaleups

Unlock the potential of your research with Cambridge Enterprise! 🌟 Our Creating Research Impact through Commercialisation event is an introductory session designed for academics, researchers, and PhD students at the University of Cambridge who are seeking guidance on transforming their research into viable commercial ventures. In this 1-hour, online session, you can learn more about the commercialisation pathways available to you: Intellectual property: Details on protecting and licensing your IP. Consulting benefits: Sharing your knowledge as a consultant. Research tools: How to license research tools and what these include (reagents, software, copyright, database rights, etc.)  Spin-out companies: Information on forming a spin-out and how Cambridge Enterprise can assist you.  Q&A session: An opportunity to get your questions answered! Event Details:  📅 Date: Thursday 26th September  🕒 Time: 12:00 – 13:00  🌐 Location: Online Click here to register: https://lnkd.in/eE9FJA8s Learn more about the Autumn Ideas to Reality Programme here: https://lnkd.in/euTykJr7 #IdeasToReality #Entrepreneurship #SocialEnterprise #Commercialisation #CambridgeInnovation

We're proud to be part of the journey for this potential new immunotherapy treatment that targets a protein found in colorectal and liver cancers. Dr Maike Heffner-de la Roche (Cancer Research UK Cambridge Institute) and Dr Marc de la Roche (Department of Biochemistry, University of Cambridge) have developed a potent new therapy called “superkiller” CAR-T cells. With the new funding from the our Translational Investment Fund (TIF) and Cancer Research Horizons, the scientists will now finalise the superkiller CAR-T cell treatment and carry out in-vivo experiments to understand how effective the new therapy could be before taking the treatment to human clinical trials. Read more in the full press release available here: https://lnkd.in/ewbyAQwt #Immunotherapy #Innovation #TranslationalFunding #Impact University of Cambridge

With less than four weeks to go, we're happy to announce we're sponsors of this year's Cambridge Tech Week! This unmissable event, running 9-13 September, brings together world-leading experts, innovators, founders, investors, startups, scale-ups, and international business. It’s going to be a fantastic opportunity to learn about the latest tech, gain invaluable insights from tech leaders, discover new startups, and just as importantly, expand our networks with a global tech audience.   The wide range of topics including quantum, semiconductors, AI, climate tech and more will prompt some lively debate. Look out for updates in the coming weeks on the daily sessions as well as the fringe events we'll be involved in. We're looking forward to seeing our colleagues and friends take the stage, and we hope to see you there! For all the info and to register, go to: https://lnkd.in/eDevWQnK   #CamTechWeek 

Innovation spotlight from our CRoSS Ideas Incubator 💡 We're thrilled to share insights from the King's Entrepreneurship Lab, authored by 3rd-year PhD candidate Ane Cornelia Pade. In “The Ideas Incubator: A Business Crash Course for an Art Historian,” Ane shares her journey of reviving the iconic Dugdill lamp and how the CRoSS Ideas Incubator at Cambridge Enterprise provided the essential skills and resources to bring her vision to life. What does the CRoSS Ideas Incubator offer? • Practical exposure to social innovation, commercialisation, and entrepreneurship. • Tailored support from a dedicated case team. • Hands-on insight, collaboration, and mentorship. • Network with like-minded innovators and develop fruitful links to Cambridges' wider research community. A special shoutout to Dr Emma Salgard Cunha, our Associate Commercialisation Director, for her invaluable guidance and to King's College, Cambridge for their collaboration! 👉 Read Ane’s full article and discover her first-hand experience: https://vist.ly/3crzc #Innovation #Entrepreneurship #Cambridge #IdeasIncubator University of Cambridge

Today Riverlane have announced a raised $75 million in Series C funding to deliver its groundbreaking quantum error correction (QEC) roadmap. “We’re thrilled to celebrate this new stage of funding for Riverlane. Their innovative approach to quantum error correction will enable the acceleration of the quantum computing industry, and we are proud to have supported their journey from the very beginning," says Dr Christine Martin, Head of Cambridge Enterprise Ventures. "This milestone highlights Riverlane’s remarkable achievements, and we look forward to witnessing their continued success and the transformative impact they will have on the industry." The funding will enable Riverlane to expand operations to meet surging global market demand for QEC technology, with the goal of achieving one million error-free quantum computer operations by 2026. The round was led by Planet First Partners, the European growth equity sustainable investment platform, with participation from sustainability venture capital investors ETF Partners and Singapore-based global investor, EDBI Pte Ltd. Existing investors Cambridge Innovation Capital, Amadeus Capital Partners, the UK's National Security Strategic Investment Fund (NSSIF), and HPC leader Altair also participated in the Series C round. Read more in the full press release available here: https://vist.ly/3cheu #Quantum #QuantumErrorCorrection #QuantumComputing #SeriesC #Investment University of Cambridge

Discover how Tenyks, a University of Cambridge spinout, is making AI safer and faster! 🤖 With passion, humility, and unbridled joy, Tenyks is inventing new ways we interact with AI. It helps enterprises understand and improve their AI models by examining the data they are using, allowing models to be deployed into production up to 10x faster. Its state-of-the-art Visual Search Engine empowers companies to unlock valuable insights from visual data across various industries. With $3.4m in funding from Cambridge Enterprise and other investors, Tenyks is on a rapid growth trajectory. Co-founders Botty Dimanov, PhD, Dmitry Kazhdan, PhD, and Maleakhi Wijaya have been recognised in Forbes’ ‘30 Under 30’, highlighting their groundbreaking contributions to the AI landscape. 🎥 | Watch the full film to learn more about Tenyks’ journey and its impact: https://vist.ly/3c839 #Cambridge #Tenyks #AI #EthicalAI #Innovation

A #ThrowbackThursday moment as we revisit earlier this year when Carbon Re released their remarkable whitepaper on the significance of embracing digitalisation to achieve #NetZero goals. This paper emphasises the importance of digitalisation in securing a resilient, profitable and sustainable future, particularly within the cement industry - a sector responsible for 8% of global carbon emissions. Carbon Re’s AI technology reduces CO2 emissions and cuts costs for cement plants by leveraging digitalisation and AI, ultimately decarbonising the cement industry. Explore how digitalisation contributes to achieving Net Zero goals in the whitepaper: Digitalisation: The Pathway to Net Zero - Carbon Re   #AI #Digitalisation #Innovation #Sustainability #NetZero #GreenInvestment

Hear from Fatima Kranc, DPhil, our Life Sciences Investment Manager, on the importance of "scientific curiosity, innovation and investment in making a real-world impact" 🧠    Q. How long have you worked for Cambridge Enterprise Ventures?    A. It has been nearly 5 years since I joined Cambridge Enterprise and became part of the amazing Ventures team. Q. What did you do before Cambridge Enterprise? A. My passion for science has been the driving force behind every step of my journey. It led me to pursue a DPhil at Oxford's Department of Cardiovascular Medicine and fuelled my research as an MRC Career Development Fellow. This same passion for translating science into tangible innovations took me beyond academia to join the consultancy team at Oxford University Innovation. There, and later at Cancer Research Horizons, I got a real sense and experience of commercializing groundbreaking discoveries. Back in 2014, supporting the formation of a pioneering drug discovery spin-out company in cancer metabolism, was a turning point that ignited my dedication to nurturing and investing in spin-out companies. This commitment brought me to Cambridge Enterprise, where I am now part of the incredible Ventures team. My journey is a testament to the power of scientific curiosity, innovation and investment in making a real-world impact. Q. Favourite industry to work with? A. As a generalist investor with a focus on life sciences and health, I thrive on the dynamic and multifaceted nature of this field. I have had the privilege of supporting innovative companies across therapeutics, AI in drug discovery, synthetic biology, and novel research tools. Each of these ventures holds a unique potential to revolutionize healthcare and improve lives and our planet, making it impossible to choose a single favourite! Q. One innovation that still blows your mind and why? A. Using condensates for drug discovery is fascinating! These membraneless “organelles” regulate crucial biochemical processes and create specialized microenvironments influencing gene expression and protein synthesis. Exploring condensates in cellular biology could lead to groundbreaking insights and new treatments for diseases. Q. What makes you lean forward and take note in a pitch? A. A business model that can create a "spin wheel" of revenues. Q. One company you wish you'd got to invest in and why? A. I’m looking to the future… Nitrogen vacancies in diamonds have recently emerged as a powerful tool in biology and disease due to their unique quantum properties. Their unparalleled sensitivity will offer new avenues for diagnosing diseases earlier and developing more effective treatments. #Ventures #LifeScience #CambridgeInnovation #Entrepreneurship